Corvus Pharmaceuticals to Present Preclinical and Early Clinical Data from the Phase 1/1b Trial with CPI-818 at the American...
November 07 2019 - 8:30AM
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of precisely targeted oncology therapies with
biomarker patient enrichment selection, today announced that it
will present preclinical and early clinical data from its Phase
1/1b clinical trial of CPI-818 at the American Society of
Hematology (ASH) 61st Annual Meeting 2019 in Orlando, Florida,
taking place December 7-10, 2019.
Corvus will present data on CPI-818 in two poster sessions:
Poster Presentations:
Poster 1571: |
Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a
Selective ITK Inhibitor that Preferentially Blocks the Growth of T
Lymphoma Cells. |
Presenter: |
Patrick Ng, PhD, Corvus Senior Scientist |
Poster Session: |
625: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents:
Poster I |
Date and Time: |
Saturday, December 7 from 5:30 pm – 7:30 pm ET |
Location: |
Poster Hall / Hall B, Level 2 / Orange County Convention
Center |
|
|
Poster 4030: |
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral
Interleukin-2 Inducible T-Cell Kinase Inhibitor, in Subjects with
Relapsed/Refractory T-Cell Lymphoma. |
Presenter: |
Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical
Officer |
Poster Session: |
624: Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies:
Poster III |
Date and Time: |
Monday, December 9, 2019 from 6:00 pm – 8:00 pm ET |
Location: |
Poster Hall / Hall B, Level 2 / Orange County Convention
Center |
About Corvus Pharmaceuticals Corvus
Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the development and commercialization of precisely
targeted oncology therapies. Corvus’ lead product candidates are
ciforadenant (CPI-444), a small molecule inhibitor of the A2A
receptor, and CPI-006, a humanized monoclonal antibody directed
against CD73 that exhibits immunomodulatory activity and blockade
of adenosine production. These candidates are being studied in
ongoing Phase 1 and 2 clinical trials in patients with a wide range
of advanced solid tumors. Ciforadenant is being evaluated in a
successive expansion cohort trial examining its activity both as a
single agent and in combination with an anti-PD-L1 antibody.
CPI-006 is being evaluated in a multicenter Phase 1/1b clinical
trial as a single agent, in combination with ciforadenant, and with
pembrolizumab. The Company’s third clinical program, CPI-818, an
oral, small molecule drug that has been shown to selectively
inhibit ITK, is in a multicenter Phase 1/1b clinical trial in
patients with several types of T-cell lymphomas. For more
information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief
Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O pure +1
213-262-9390 sseapy@purecommunications.com
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Apr 2023 to Apr 2024